RxDoctor Payments Data

Deborah Caputo, APRN

Family · Neptune, NJNPI 1013105634

Payments from drug & device makers

$3,822in general payments, 2019–2025

Across 149 payments — averaging $25.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$942
  • Medtronic$409
  • Boston Scientific$322
  • Amneal Pharmaceuticals LLC$306
  • Acadia Pharmaceuticals Inc$299
  • Insightec,inc$271
  • plus $1K from 20 others
$210in research payments, 2019–2025

Across 1 payment — averaging $210.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Medtronic$210

What the payments were for

  • Food & beverage$3,65095%
  • Education$1725%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,822 in reported general payments places this provider in the 90th percentile of 2,692 family providers in New Jersey.

See all family providers in New Jersey

Medicare billing

Part B allowed, 2024
$53,771
Medicare patients
145
Services billed
494

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RytaryCarbidopa/Levodopa324$474,167
NuplazidPimavanserin Tartrate33$252,984
Carbidopa-LevodopaCarbidopa/Levodopa615$31,584
Rasagiline Mesylate60$19,504
Entacapone38$8,144
Carbidopa-Levodopa ErCarbidopa/Levodopa116$4,642
Rivastigmine12$4,297
AmantadineAmantadine Hcl65$3,501
Quetiapine Fumarate100$2,576
Primidone54$2,172
Mirtazapine70$1,790
Ropinirole Hcl27$1,578
Gabapentin57$1,522
Donepezil Hcl58$1,515
Escitalopram Oxalate60$1,446

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Amneal Pharmaceuticals LLCRytary$306$474,167324 claims
Acadia Pharmaceuticals IncNuplazid$299$252,98433 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,692 family providers in New Jersey.

Other family in Neptune

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →